NasdaqGS:PTCTBiotechs
PTC Therapeutics (PTCT) On Russell Index Inclusion And Pipeline Optimism With Fair Value In Focus
PTC Therapeutics (PTCT) is back in focus after its recent addition to three Russell 2000 Defensive indexes, with attention also centering on two NDAs under FDA review and a potential Phase 3 Huntington's disease program.
See our latest analysis for PTC Therapeutics.
Over the past year, PTC Therapeutics has combined strong momentum with index-related interest, with the share price delivering a 12.92% 1 month share price return and a 74.77% 1 year total shareholder return as investors weigh its...